PsyMed Ventures
VC Fund
San Francisco, United States
Psymed Ventures is an investment syndicate that invests in early-stage psychedelics companies. The firm was founded in 2020 by Matias Serebrinsky and Dina Burkitbayeva and is headquartered in San Francisco, California, United States.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 0%
- Fund size:
- $10M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries PsyMed Ventures invests in
Stages PsyMed Ventures invests in
Countries PsyMed Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $680k–$21M
- Pre-Seed
- $3.5M–$8M
- Series A
- $4.8M–$70M
Investment Focus
Industry
- Health Care 13 (50%)
- Biotechnology 11 (42%)
- Medical 7 (27%)
- Therapeutics 4 (15%)
- Neuroscience 3 (12%)
Stage
- Seed 9 (35%)
- Series A 9 (35%)
- Pre-Seed 2 (8%)
- Venture - Series Unknown 2 (8%)
- Series B 1 (4%)
Country
- United States 15 (58%)
- Canada 1 (4%)
- Israel 1 (4%)
- Ireland 1 (4%)
- Australia 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Caitlin Ner
Chief of Staff; Chief of Staff
|
Chief of Staff; Chief of Staff | Total investments: 0 | Find email | |
Dina Burkitbayeva
Founder
|
Founder | Total investments: 2 | Find email | |
Garri Zmudze
Venture Partner
|
Venture Partner | Total investments: 9 | Find email | |
Greg Kubin
Founder
|
Founder | Total investments: 0 | Find email | |
Matias Serebrinsky
Co-founder and General Partner
|
Co-founder and General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Remepy is biotechnology research pioneering hybrid drugs. The company believes that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms ofAction™.It was founded in 2022 and is located in Ramat Gan, Tel Aviv. | $36M / Series A / Aug 12, 2026 | ||
| Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders. | $21M / Seed / Oct 01, 2025 | ||
Sanmai
|
Sanmai is a neurotechnology company developing non-invasive ultrasound neurotherapeutics for mental health and neurological disorders | Jun 23, 2025 | |
|
Sanmai
|
Sanmai is a neurotechnology company developing non-invasive ultrasound neurotherapeutics for mental health and neurological disorders | $12M / Series A / Jun 23, 2025 | |
| Jimini’s mission is to radically improve the efficacy of mental health care across the world. Jimini has developed a novel care model that combines teletherapy sessions with personalized AI support. With Jimini, your therapy care team includes your licensed clinician and Sage, your always-available AI therapy assistant, who work together to helpyou achieve your goals.Founded in 2023 by a team of seasoned AI and biotech entrepreneurs, health tech veterans, and psychology researchers, Jimini puts science and tech first, using safe, purpose-built patient-facing technology that works exclusively under clinical oversight and high safety standards.World leaders in psychology designed Jimini’s care model to ensure that every part of the patient's journey is clinically beneficial. Jimini does not believe that LLMs should replace clinicians; rather, AI will help therapists deliver higher-quality care and focus on the most complex parts of their job. Jimini’s care model is first and foremost led by excellent clinicians.Jimini is committed to improving mental health quality and creating radically better, more modern, and clinically efficacious mental health experiences for patients. | $8M / Pre-Seed / Nov 19, 2024 | ||
| Neurode is developing a non-invasive wearable device to improve cognitive performance for people with neurological conditions like ADHD. The headset aims to treat and monitor the symptoms of ADHD as well as a paired app that tracks your improvements and shares them with your clinician. | $3.5M / Pre-Seed / Sep 13, 2024 | ||
| Ancilia Biosciences develops engineered bacterial therapies to treat diseases linked to the microbiome. It provides and develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. | $4.2M / Venture - Series Unknown / Jul 17, 2024 | ||
| Remepy is biotechnology research pioneering hybrid drugs. The company believes that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms ofAction™.It was founded in 2022 and is located in Ramat Gan, Tel Aviv. | $10M / Seed / May 01, 2024 | ||
| Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses. | $18.8M / Series A / Jan 24, 2024 | ||
| Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses. | $2M / Seed / Feb 28, 2023 | ||
| See all 26 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does PsyMed Ventures invest in?
PsyMed Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is PsyMed Ventures's check size?
PsyMed Ventures typically joins rounds of $680k–$21M at Seed, $3.5M–$8M at Pre-Seed and $4.8M–$70M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds PsyMed Ventures participates in.
How do I contact PsyMed Ventures?
Public channels for PsyMed Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at PsyMed Ventures?
The team at PsyMed Ventures includes Caitlin Ner (Chief of Staff; Chief of Staff), Dina Burkitbayeva (Founder) and Garri Zmudze (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
